Chenodeoxycholic Acid ( DrugBank: Chenodeoxycholic acid )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
20副腎白質ジストロフィー1
96クローン病1
234ペルオキシソーム病(副腎白質ジストロフィーを除く。)1
263脳腱黄色腫症4

20. 副腎白質ジストロフィー


臨床試験数 : 61 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00004442
(ClinicalTrials.gov)
September 199718/10/1999Study of Bile Acids in Patients With Peroxisomal DisordersInfantile Refsum's Disease;Zellweger Syndrome;Bifunctional Enzyme Deficiency;AdrenoleukodystrophyDrug: chenodeoxycholic acid;Drug: cholic acid;Drug: ursodiolChildren's Hospital Research Foundation University of CincinnatiChildren's Hospital Medical Center, CincinnatiTerminatedN/A5 YearsBoth25N/ANULL

96. クローン病


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-013348-35-NL
(EUCTR)
04/08/200903/07/2009(Patho)Physiological aspects of the bile salt-FXR-FGF19-axis: potential consequences in Crohn's disease. - Bile acid-FXR-FGF19 functioning in Crohn's disease(Patho)Physiological aspects of the bile salt-FXR-FGF19-axis: potential consequences in Crohn's disease. - Bile acid-FXR-FGF19 functioning in Crohn's disease Patients with quiescent Crohn’s colitis, defined as a Crohn’s Disease Activity Index <150 ; non-IBD patients will serve as disease controls.
MedDRA version: 9.1;Level: LLT;Classification code 10011400;Term: Crohn's colitis
MedDRA version: 9.1;Classification code 10011401;Term: Crohn's disease
MedDRA version: 9.1;Classification code 10011402;Term: Crohn's disease (colon)
Trade Name: Chenofalk
Product Name: Chenofalk
Product Code: RVG 07151
INN or Proposed INN: CHENODEOXYCHOLIC ACID
Other descriptive name: Chenodiol
University Medical Center UtrechtNULLNot RecruitingFemale: yes
Male: yes
Netherlands

234. ペルオキシソーム病(副腎白質ジストロフィーを除く。)


臨床試験数 : 39 薬物数 : 35 - (DrugBank : 12) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 45
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00004442
(ClinicalTrials.gov)
September 199718/10/1999Study of Bile Acids in Patients With Peroxisomal DisordersInfantile Refsum's Disease;Zellweger Syndrome;Bifunctional Enzyme Deficiency;AdrenoleukodystrophyDrug: chenodeoxycholic acid;Drug: cholic acid;Drug: ursodiolChildren's Hospital Research Foundation University of CincinnatiChildren's Hospital Medical Center, CincinnatiTerminatedN/A5 YearsBoth25N/ANULL

263. 脳腱黄色腫症


臨床試験数 : 6 薬物数 : 11 - (DrugBank : 2) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 4
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-205157
03/8/202013/02/2020An open-label study of FPF1011 in patients with cerebrotendinous xanthomatosis (phase 3)An open-label study of FPF1011 in patients with cerebrotendinous xanthomatosis (phase 3) Cerebrotendinous xanthomatosisIntervention name : FPF1011
INN of the intervention : Chenodeoxycholic acid
Dosage And administration of the intervention : Dose of chenodeoxycholic acid is 750 mg/day for patients aged 20 or older, and 15 mg/kg/day under ages 20, administered orally in three divided doses a day.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Fujimoto Pharmaceutical CorporationNULLrecruiting0BOTH5Phase 3Japan
2NCT04270682
(ClinicalTrials.gov)
January 31, 202012/2/2020Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)A Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients With Cerebrotendinous XanthomatosisCTXDrug: Blinded CDCA 250 mg TID;Drug: Placebo;Drug: Open-Label CDCA 250 mg TID;Drug: Rescue Medication CDCA 250 mg TID;Drug: CDCA Weight-Based Dose TIDTravere Therapeutics, Inc.NULLRecruiting1 MonthN/AAll12Phase 3United States;Brazil
3NCT00018694
(ClinicalTrials.gov)
October 19993/7/2001Cholestanol in HumansBiologic Significance of Cholestanol in ManCerebrotendinous XanthomatosisDrug: Chenodeoxycholic AcidDepartment of Veterans AffairsNULLWithdrawn5 Years80 YearsBoth0N/AUnited States
4NCT00004346
(ClinicalTrials.gov)
January 199618/10/1999Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous XanthomatosisEffects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)Cerebrotendinous XanthomatosisDrug: chenodeoxycholic acid;Drug: lovastatinNational Center for Research Resources (NCRR)Oregon Health and Science UniversityRecruitingN/AN/ABoth5Phase 2United States